The development of targeted therapies for non-small cell lung cancer (NSCLC), such as the
epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase …

Abstract PROteolysis Targeting Chimeras (PROTACs) showed tremendous therapeutic
potential in degrading several oncoproteins including undruggable proteins. PROTACs are …

Simple Summary Lung cancer patients with a specific gene mutation often undergo tissue
biopsies to guide treatment. But what if a simple blood test could do the same? This review …

BACKGROUND Although common in lung cancer, somatic epidermal growth factor receptor
(EGFR) mutations are rarely found in colorectal cancer, occurring in approximately 3% of …

Background Lung cancer remains the leading cause of cancer-related death worldwide.
Targeted therapies with tyrosine kinase inhibitors (TKIs) result in improvement in survival for …

Background Resistance restricts the long-term therapeutic efficacy of epidermal growth
factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of non-small cell lung …

Objective The predictive value of serum tumor markers (STMs) in assessing epidermal
growth factor receptor (EGFR) mutations among patients with non-small cell lung cancer …

The development of small molecule anti-tumor drugs has emerged as a promising strategy
for cancer treatment, meanwhile the EGFR is associated with tumor formation and …

Background: Colorectal cancer (CRC) is the leading cause of cancer deaths, and treatment,
especially in the metastatic stage, is challenging. Immune checkpoint inhibitors (ICIs) have …

Background: We conducted this meta-analysis based on updated literature and research to
compare the efficacy and safety of epidermal growth factor receptor tyrosine kinase …